The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Open accessAbstract
In multiple sclerosis (MS), B cell–depleting therapy using monoclonal anti-CD20 Abs, including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. Based on indirect evidence, it is generally believed that elimination of the Ag-presenting capabilities and Ag nonspecific immune functions of B cells underlie the therapeutic efficacy. However, a small subset of T lymphocytes (T cells) was shown to also express CD20, but controversy prevails surrounding the true existence of this T cell subpopulation. Using single-cell imaging flow cytometry and expression profiling of sorted lymphocyte subsets, we unequivocally demonstrate the existence of CD3+CD20dim T cells. We show that in MS patients, increased levels of CD3+CD20dim T cells are effectively depleted by RTX. The pathological relevance of this T cell subset in MS remains to be determined. However, given their potential proinflammatory functionality, depletion of CD20-expressing T cells may also contribute to the therapeutic effect of RTX and other mAbs targeting CD20.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationImmunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
A framework for oligonucleotide microarray preprocessing
Carvalho, B. S., & Irizarry, R. A. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq431 · Cited by 1,550
Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., Friese, M., Schröder, R., Deckert, M., Schmidt, S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.393 · Cited by 951
arrayQualityMetrics—a bioconductor package for quality assessment of microarray data
Kauffmann, A., Gentleman, R., & Huber, W. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btn647 · Cited by 946 · cited 1×
“Quality of the analyzed arrays was ascertained using the arrayQualityMetrics package (10).”
MethodMaloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Self-citationWei, C., Anolik, J., Cappione, A., Zheng, B., Pugh-Bernard, A., Brooks, J., Lee, E.-H., Milner, E. C. B., & Sanz, I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6624 · Cited by 604
Leandro, M. J., Cambridge, G., Ehrenstein, M. R., & Edwards, J. C. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21617 · Cited by 560
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?
Bar‐Or, A., Fawaz, L., Fan, B., Darlington, P. J., Rieger, A., Ghorayeb, C., Calabresi, P. A., Waubant, E., Hauser, S. L., Zhang, J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21939 · Cited by 521
Self-citationRituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J.-A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 454
Myelin Antigen-Specific CD8+ T Cells Are Encephalitogenic and Produce Severe Disease in C57BL/6 Mice
Sun, D., Whitaker, J. N., Huang, Z., Liu, D., Coleclough, C., Wekerle, H., & Raine, C. S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7579 · Cited by 444
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions
Hauser, S. L., Bhan, A. K., Gilles, F., Kemp, M., Kerr, C., & Weiner, H. L. (1986) · Annals of Neurology · doi:10.1002/ana.410190610 · Cited by 399
Self-citationCD20 deficiency in humans results in impaired T cell–independent antibody responses
Kuijpers, T. W., Bende, R. J., Baars, P. A., Grummels, A., Derks, I. A. M., Dolman, K. M., Beaumont, T., Tedder, T. F., van Noesel, C. J. M., Eldering, E., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40231 · Cited by 375
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis
Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2395 · Cited by 347
Self-citationWeber, M. S., Prod'homme, T., Patarroyo, J. C., Molnarfi, N., Karnezis, T., Lehmann‐Horn, K., Danilenko, D. M., Eastham‐Anderson, J., Slavin, A. J., Linington, C., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22081 · Cited by 318
Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
Piccio, L., Naismith, R. T., Trinkaus, K., Klein, R. S., Parks, B. J., Lyons, J. A., & Cross, A. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.99 · Cited by 274
Crawford, M. P., Yan, S. X., Ortega, S. B., Mehta, R. S., Hewitt, R. E., Price, D. A., Stastny, P., Douek, D. C., Koup, R. A., Racke, M. K., et al. (2004) · Blood · doi:10.1182/blood-2003-11-4025 · Cited by 250
Cd20 (pan‐B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes
Hultin, L. E., Hausner, M. A., Hultin, P. M., & Giorgi, J. V. (1993) · Cytometry · doi:10.1002/cyto.990140212 · Cited by 204
Modeling the heterogeneity of multiple sclerosis in animals
Simmons, S. B., Pierson, E. R., Lee, S. Y., & Goverman, J. M. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.04.006 · Cited by 174
Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides.
Tsuchida, T., Parker, K. C., Turner, R. V., McFarland, H. F., Coligan, J. E., & Biddison, W. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10859 · Cited by 159
Huang, H., Benoist, C., & Mathis, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001074107 · Cited by 159
Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling
Walshe, C. A., Beers, S. A., French, R. R., Chan, H. T. C., Johnson, P., Packham, G., Glennie, M. J., & Cragg, M. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708459200 · Cited by 153
Depletion of functionally active CD20+ T cells by rituximab treatment
Wilk, E., Witte, T., Marquardt, N., Horváth, T., Kalippke, K., Scholz, K., Wilke, N., Schmidt, R. E., & Jacobs, R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24998 · Cited by 152
B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
Herbst, R., Wang, Y., Gallagher, S., Mittereder, N., Kuta, E. G., Damschroder, M. M., Woods, R., Rowe, D. C., Cheng, L., Cook, K., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168062 · Cited by 141
Relapsing-remitting CNS autoimmunity mediated by GFAP-specific CD8 T cells
Sasaki, K., Bean, A., Shah, S., Schutten, E., Huseby, P. G., Peters, B., Shen, Z. T., Vanguri, V., Liggitt, D., & Huseby, E. (2014) · Journal of Immunology · doi:10.4049/jimmunol.1302911 · Cited by 106
Monson, N. L., Cravens, P. D., Hussain, R. Z., Harp, C. T., Cummings, M., Martin, M. D. P., Ben, L.-H., Do, J., Lyons, J., Lovett‐Racke, A. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017103 · Cited by 84
Eggleton, P., Bremer, E., Tarr, J. M., de Bruyn, M., Helfrich, W., Kendall, A. C., Haigh, R. C., Viner, N. J., & Winyard, P. G. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3541 · Cited by 75
Castillo, J. J., Milani, C., & Mendez-Allwood, D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902832679 · Cited by 68
Yan, Y., Li, Z., Zhang, G., Williams, M. S., Carey, G. B., Zhang, J., Rostami, A. M., & Xu, H. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0870-2 · Cited by 17
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Self-citationMultiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Metadata
- Authors
- Palanichamy, A., Jahn, S., Nickles, D., Derstine, M., Abounasr, A., Hauser, S. L., Baranzini, S. E., Leppert, D., & von Büdingen, H.-C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07
- Volume
- 193
- Issue
- 2
- Pages
- 580-586
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2126336004
- Cited by
- 289
- References
- 32
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.